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THE CONCEPT OF SYNOVIAL CELL ACTIVATION 
Rheumatoid arthritis is exclusively a disease of man, and lack of an experi- 
mental animal model has impeded progress in understanding the etiology and 
pathogenesis of this destructive process. At the level of the synovial membrane, 
the rheumatoid process is characterized by intermittent connective tissue cell 
proliferation, overproduction of underpolymerized hyaluronic acid,’ increased 
glycolysis,2 colonization by various types of inflammatory cells, and abnormali- 
ties of the microvasculature.3 In the hope of developing a relevant in vitro 
investigative model, this laboratory established 61 synovial cell strains from 
normal individuals and patients with different forms of arthritis. The “abnor- 
malities” detected in the rheumatoid cell strains (TABLE 1) were of particular 
interest, because these characteristics were propagated from one generation of 
cells to the Efforts to reproduce the “rheumatoid” characteristics in 
normal synovial cells by adding rheumatoid sera to the media lead to minor and 
inconsistent alterations in cellular behavior.‘j 
Because evidence for humoral factors capable of inducing “rheumatoid 
behavior” in normal synovial cells was weak, we next examined the response of 
normal synovial cells to selected cellular factors. Isolated human peripheral 
blood lymphocytes, polymorphonuclear leukocytes, and platelets were cocultured 
with monolayer cultures of normal human synovial cells and found to cause 
profound changes in culture activity. These changes included decreased medium 
pH, marked acceleration of hyaluronic acid synthesis, and striking increases in 
glucose uptake and lactic acid formation.’ It soon became clear that slurries 
of dead leukocytes (frozen-thawed) elicited the same hypermetabolic synovial 
cell response. Extracts of both syngeneic and allogeneic leukocytes stimulated 
synovial cells, and because of its protease lability, performance on gel permea- 
tion columns, and nondialyzability, the active factor was thought to be a low- 
molecular-weight protein.*, Q We termed the constellation of accelerated hy- 
aluronate synthesis, increased glucose uptake, and increased lactate formation 
connective tissue activation, and the cellular mediator( s) that initiate( s )  this 
process was named connective tissue activating peptide (CTAP) .9 Major sources 
and actions of CTAP are summarized in FIGURE 1. 
* Supported by United States Public Health Service Grant AM-10728 and by the 
Michigan Chapter of the Arthritis Foundation. 
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FIGURE 1. CTAP from diverse sources has the capability of interacting in vitro 
with human synovial cells to produce the consequences listed (right). Although most 
of the metabolic responses are consistent with in vivo expectations, it seems likely 
that the depressed collagen formation is an artifact of the closed in vitro system, pos- 
sibly in part related to substrate limitation. (From Castor." By permission of The 
Journal of Laboratory and Clinical Medicine.) 
ISOLATION A D CHARACTERIZATION F CTAP 
Extraction of CTAP biologic activity from convenient sources, such as 
human spleen and long-term lymphocyte cultures, has been accomplished with 
water, buffered saline, 0.25 M sucrose, 0.1 M glycine buffer (pH 2.2), acid 
ethanol (80% ethanol, 20% 1.25 N HCI), and even 0.25 N sulfuric acid. Early 
experiments were hampered by the marked lability of CTAP biologic activity, 
a problem partly resolved when it proved possible to protect the activity by 
addition of 2-mercaptoethanol to the extraction vehicle. In later experiments, 
CTAP biologic activity was destroyed by alkylation or mercaptide formation, 
which fact also suggested that the peptide factor contained an essential sulfhydryl 
m ~ i e t y . ~  Gel permeation chromatography showed that CTAP biologic activity 
was retarded on Sephadexs G-SO and Bio Gel@ P-10 but that it appeared in 
the void volume from Sephadex G-25 and Bio Gel P-6 columns. CTAP does 
not bind to DEAE-Sephadex A-25 at neutral pH but does bind to carboxy- 
methyl- (CM) cellulose 32. 
TABLE 1 
"ABNORMALITIES" OF RHEUMATOID SYNOVIAL CELLS 
Slower growth rate 
Increased hyaluronic acid synthesis rate 
Produce hyaluronic acid of lesser MW 
Increased glycolytic metabolism 
Hyporesponsive to cortisol regulation * of mitosis, hyaluronate synthesis, collagen syn- 
thesis, and cell volume 
Increased endogenous CTAP 
* Cortisol, 1.0 pg/ml, stimulates mitosis of normal synovial cells by 44%, de- 
presses HA synthesis by 54%, depresses collagen synthesis by SO%, and reduces mean 
cell volume by 19%. 
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Although CTAP was effectively extracted from solid tissues by acidic 
vehicles, the resultant extracts contained substantial quantities of histones and 
proved difficult to fractionate. To reduce histone contamination, we have 
returned to neutral saline extraction in the presence of 0.1 % 2-mercaptoethanol. 
Our current procedure for isolation of CTAP is depicted in FIGURE 2. A 
"stage-VI" preparation usually has one to four bands on polyacrylamide disc 
gel electrophoresis at pH 9.5 in 9 or 15% gels. Fractions eluted from CM- 
cellulose 32 may be concentrated by rotary evaporation at 30" C in the presence 
of small amounts of glycerol. To prevent loss of peptide due to binding to 
glassware, it proved helpful to treat with trimethylchlorosilane all glassware in 
contact with purified CTAP preparations. Both crude and purified CTAP 
preparations from spleen, cultured lymphocytes, and Hep-2 cells retain biologic 
activity for weeks if stored frozen at 4" C in the presence of 0.1 % 2-mercapto- 
ethanol or 0.001 M dithiothreitol or dithioerythritol. Lyophilized preparations 
retained activity for at least 1 month on storage at -70" C. Crude extracts of 
mixed leukocytes, however, lose biologic activity relatively rapidly. 
A preliminary amino acid analysis of virtually homogeneous CTAP derived 
from long-term human lymphocyte cultures is listed in TABLE 2. The amino 
acid composition of CTAP from cultured lymphocytes closely resembles that 
found earlier for human spleen CTAP by semiquantitative chromatographic 
methods. Aromatic amino acid residues were relatively sparse, whereas dicar- 
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FIGURE 2. With the preparative scheme above, recovery of CTAP appears to range 
from 50 to 80%. This isolation sequence has been successfully applied to long-term 
normal lymphocyte cultures, media from such cultures, the Hep-2 cell strain, and to 
human spleen. 
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TABLE 2
AMINO ACID COMPOSITION OF CTAP FRACTION * 
FROM LONG-TERM HUMAN LYMPHOCYTE LINE 
Number of 
Amino Acid Residues 
Aspartic acid 14 
















Total residues 142 
Molecular weight 15,3 18 daltons 
This fraction had a specific biologic activity of 49 CTAP units/mg protein and 
appeared to be nearly homogeneous on electrophoresis at pH 9.5 in 15% polyacryla- 
mide gels. The biologic activity elutes from a 1 x 30-cm Sephadex G-50 fine column 
at the same volume as does cytochrome c. 
boxylic acids comprised nearly 25% of the residues. In view of the apparently 
basic nature of the peptide, and the ammonia measured during amino acid 
analysis, it seems likely that a substantial portion of the dicarboxylic acids exist 
as glutamine and asparagine in the native peptide. The presence of three half- 
cystine residues confirms the presence of at least one free sulfhydryl group. 
Chromatography on Sephadex G-50 (F)  revealed that lymphocyte CTAP had 
the same elution volume as cytochrome c (MW = 12,384 daltons), a finding 
in fair agreement with the estimate of 15,318 daltons derived from amino acid 
analysis. Splenic CTAP also elutes from Sephadex G-50 with the same elution 
volume as cytochrome c. 
ASSAY OF CTAP 
Bioassay of CTAP was achieved with 1.0 X lo6 normal human synovial 
cells per T-15 flask. Cells were planted in standard medium (80% 1066, 10% 
human serum, 10% fetal calf serum supplemented with I-glutamine, penicillin, 
and streptomycin) and allowed to attach and spread on the glass surface for 
4-6 hr. Serum-containing medium was then removed and replaced with 2.0 
ml of “assay medium” (Eagle’s synthetic medium buffered to pH 7.6 with 0.02 
M HEPES). Test samples and appropriate vehicle controls were added in 
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volumes that ranged from 0.05 to 0.30 ml per flask, and then the assay flasks 
were incubated for 40 hr at 35-37°C. At the conclusion of the incubation 
period, cell sheets were washed twice with neutral buffered saline, and the 
protein was measured by the method of Oyama and Eagle.Io Hyaluronic acid 
in the culture medium was measured in terms of its uronic acid moiety by a 
modified carbazole method after isolation of the polymer.E Residual medium 
glucose was measured by a glucose oxidase method,12 and lactate was deter- 
mined by the Barker-Summerson procedure.I3 Because earlier studies demon- 
strated that the amount of hyaluronic acid synthesized by the incubated synovial 
cells was proportional to incubation time and the amount of CTAP added, we 
arbitrarily defined a "CTAP unit" in terms of the relation 
(unit/ml), A ,  --A, 
10 v CTAP = 
where A ,  is the hyaluronic acid synthesis rate (pg/mg cell protein/24 hr) in 
the experimental flasks, and A, is this measurement in control (vehicle-treated) 
flasks. The term V represents the volume (ml) of test material. 
BIOLOGIC SIGNIFICANCE OF CTAP 
To  evaluate the CTAP content of an evolving granuloma in v ivo ,  cotton 
pellets were implanted subcutaneously in Sprague-Dawley rats, and the re- 
sultant granulomas were harvested at intervals after imp1antati0n.l~ The CTAP 
concentrations in granulomas (units of CTAP/ 100 pg DNA) were elevated at 
Day 4, reached a peak at Day 7, and returned to low levels by Day 14 (FIGURE 
3). The hyaluronic acid concentrations in the granulomas were also greatest 
at Day 7, whereas sulfated mucopolysaccharides reached their greatest concen- 
trations by Day 14 (FIGURE 4).  Collagen was present in high concentrations 
by Day 7 and increased slightly over the next 3 weeks. Polymorphonuclear 
leukocytes were the dominant cell type at Day 4, but by Day 7, the granuloma 
was primarily populated by fibrocytes and foreign body giant cells. The elevated 
level of CTAP found early in the inflammatory process is consonant with its 
postulated role as a regulator of the transition from the exudative to the repara- 
tive phase of inflammation. Further, the concomitant peak concentration of 
hyaluronate in the granuloma is in accord with the in vitro actions of CTAP 
that we have described. 
20 r 
FIGURE 3. CTAP flux in cotton pellet granu- 
lomas followed for 28 days. Vertical bars at 
data points reflect the range of the measure- 
ments. (From Castor." By permission of The 
Journal of Laboratory and Clinical Medicine.) 
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FIGURE 4. The time course of HA and sul- 
fated glycosaminoglycan concentrations in rat 
cotton pellet granulomas is recorded. Vertical 
bars at the data points indicate the standard 
error of the mean from four sets of measure- 
ments for HA and five sets of measurements 
for the sulfated glycosaminoglycans. The two 
early HA concentrations (Days 4 and 7) were 
significantly (p < 0.01) larger than those at 
Days 14 and 21. (From Ca~tor.’~ By permis- 
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Rheumatoid synovial cells in vitro were relatively unresponsive to exogenous 
CTAP,15 an observation that suggested that rheumatoid cells might be “ab- 
normal” (TABLE 1) by virtue of increased endogenous CTAP content. When 
CTAP was extracted from seven normal and seven rheumatoid cell strains, and 
the extracts were assayed simultaneously, the rheumatoid strains were found to 
have approximately four times the CTAP activity found in normal synovial 
cells. Most of the abnormal metabolic properties listed in TABLE 1 for rheuma- 
toid cell strains may be attributable to the elevated endogenous CTAP levels in 
rheumatoid cells. Although detection of increased cellular CTAP activity may 
come closer to identifying a primary defect in rheumatoid synovial cells, there 
is no obvious etiologic reason for this phenomenon. Because the retention time 
of CTAP added to normal cultures is only a few days at most, it seems unlikely 
that increased endogenous CTAP in rheumatoid cells is a legacy from previous 
contacts with inflammatory leukocytes. 
Plasma levels of CTAP have been found elevated in more than two-thirds 
of patients with active rheumatic diseases, whereas patients whose disease was 
suppressed with glucocorticoid or cytotoxic agents had CTAP levels in the 
normal range.16 Although CTAP is detectable in plasma, more than 60% of 
the biologic activity in circulating blood resides in the leukocytes and platelets. 
Joint fluid from patients with traumatic arthritis, osteoarthritis, and rheumatoid 
arthritis contained detectable concentrations of CTAP, whereas the leukocytes 
from these effusions displayed very little activity. 
Splenic tissue from infants has repeatedly proved to be a poor source of 
CTAP. In the same vein, extracts of fetal mouse brain and rat limb buds 
(19 day) had low, although measureable, levels of this biologic activity. Crude 
extracts of human spleens involved by plasmacytic myeloma also exhibited low 
concentrations of CTAP. Most startling was the observation’ that circulating 
leukocytes from several types of uncontrolled human leukemia had virtually no 
CTAP activity. It is unclear whether these “CTAP-poor” states, while sharing 
the characteristic of being inadequately or abnormally differentiated, have a 
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common denominator that explains these findings. The possibility of inhibitory 
substances in the crude extracts needs serious study. 
SPECIFICITY OF TARGET CELLS AND AGONISTS 
The Target Cells 
The spectrum of connective tissue cells capable of exhibiting increased 
hyaluronate synthesis and energy utilization on exposure to CTAP has received 
inadequate attention. To date, only synovial fibroblasts (human and canine), 
human retroorbital fibroblasts, and mesothelioma cells have been shown to be 
responsive to “conventional” CTAP (derived from human spleen, leukocytes, 
Hep-2 tissue culture cells, and canine spleen). Dermal fibroblasts in cell culture 
are not stimulated to produce incremental hyaluronate by “conventional” CTAP 
but do respond to extracts of dermal fibroblasts themselves.“ Human dermal 
fibroblasts also demonstrate increased glycosaminoglycan synthesis on exposure 
to dibutyryl cyclic AMP and prostaglandin (PG)E,.17. l h  It is possible that 
there may be multiple CTAP-like substances with tissue or organ specificities. 
Studies wherein primary fibroblast strains from many anatomic sites are exposed 
to purified, characterized CTAP from many sources should shed light on this 
question. 
The Agonists 
As can be seen in TABLE 3,  several agents are capable of stimulating synovial 
cells to form increased quantities of hyaluronic acid. It is clear, however, that 
in most cases, these agonists are not found in such supraphysiologic concentra- 
tions in vivo,  and some of the other agents do not occur naturally. CTAP is 
the most potent agent for stimulating synovial cell hyaluronate synthesis, fol- 
lowed by PGE,, dibutyryl cyclic AMP, and endotoxin. Both PGE, and 
dibutyryl cyclic AMP not only stimulate synovial cells directly in the high 
concentrations recorded in TABLE 3 but will also potentiate the effect of CTAP 
when they are added to cultures in low concentrations that are not stimulatory 
in their own right.17, l8 The stimulatory effect of endotoxins probably derives 
in large part from the lipid-A component of these There is some 
evidence to suggest that endotoxin may activate synovial cells by inducing 
increased levels of endogenous CTAP.20 Some low-molecular-weight basic ma- 
terials that do not display “CTAP-stimulating” activity are listed in TABLE 4. 
In some cases, the agents appear to inhibit basal hyaluronate synthesis. Po~Y-L- 
arginine (MW = 65,000) is actually a potent in vitro inhibitor of CTAP-induced 
synovial cell activation. 
INHIBITORS OF SYNOVIAL CELL ACTIVATION 
A partial list of agents that interfere with CTAP-induced activation of 
synovial cells is found in TABLES 5 and 6.lX3 Actinomycin D inhibits 
activation only if added within 2 hr of the CTAP stimulus, whereas cyclohexi- 
mide is effective when added as late as 6 hr post CTAP. The conventional anti- 
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TABLE 3 
SYNOVIAL CELL ACTIVATION: EFFECTIVE AGENTS 
Agent 
“Specific” 
Concentration Hyaluronate (explcont 
Incremental Ratio 
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TABLE 4 
SYNOVIAL CELL ACTIVATION : INEFFECTIVE AGENTS 
Substance Tested 
Incremental 






Eosinophil granule basic protein t 
Protamine 
Spermine 
Pol y-L-l ysine 
Pol y-~-arginine 
Histones (Sigma) 
Calf thymus mixture 
Calf thymus mixture 
Type I11 (lysine rich) 
Type IV (f3, arginine rich) 
Type VI (fZa) 































* Rates expressed as pg HA/mg cell protein124 hr. 
t A gift of Dr. Gerald J. Gleich (preparation described in J. Exp. Med. 137: 1459, 
1973). 
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TABLE 5
INHIBITORS OF SYNOVIAL CELL ACTIVATION 
Effective 
Concentration 
Agent ( d r n l )  
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inflammatory drugs (TABLE 5 )  are effective inhibitors at levels usually achieved 
in the plasma of patients who receive these agents. 7-Oxa-13-prostynoic acid 
not only blocks CTAP-induced hyaluronate (HA) synthesis but also interferes 
with PGE, stimulation of HA synthesis in synovial cells. The adrenergic 
blocking agents and imipramine probably do not act via specific receptor site 
blockade but may be active through their membrane-stabilizing properties. 
Ethacrynic acid, imipramine, and the adrenergic blocking agents suppress HA 
synthesis, even when added to cultures 16 hr post CTAP, and the bulk of the 
evidence suggests that they act on the HA-synthesizing mechanism itself. 
MECHANISM OF CTAP-INDUCED SYNOVIAL CELL ACTIVATION 
The mechanism by which CTAP induces synovial cell activation may be 
tentatively represented as illustrated in FIGURE 5. CTAP may be visualized as 
CTAP 
FIGURE 5. Synovial cell activation. CTAP is represented as interacting with a two- 
component receptor site and triggering two essential, but independent, reaction se- 
quences that result in “activation” of the synovial cell. 
interacting with a complex cell membrane receptor site that possesses at least 
two essential components. Component I initiates the sequence of events in the 
upper arcade that leads to obligatory protein synthesis (presumably enzymes 
important to the glycolytic and HA synthesis pathways) and prepares the cell 
for large-scale synthesis of hyaluronic acid. Component I1 is believed to initiate 
a prostaglandin-cyclic AMP interaction that mobilizes both energy and carbon 
to meet the needs of the impending synthetic effort. Evidence to support a 
role for endogenous (synovial) prostaglandin synthesis includes inhibition of 
CTAP-induced activation by prostaglandin antagonists; inhibition of CTAP- 
induced activation by inhibitors of prostaglandin synthesis, such as aspirin and 
indomethacin; reversal of indomethacin inhibition by PGE, and dibutyryl 
cyclic AMP; and similar magnitude of accumulation of synovial cell cyclic 
AMP caused by CTAP and “potentiating” levels of exogenous PGE,. 
Our belief that the receptor site must have at least two components derives 
from two observations. First, both cortisol and cycloheximide block the action 
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ETIOLOGIC AGENTS (INJURY) 
FIGURE 6. Simple inflammation. 
connects the acute and reparative 
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FIGURE 7. Rheumatoid inflammation. The coupling of immune processes and the 
complement mechanism to simple inflammation suggest many avenues for tissue de- 
struction and many reasons for the “self-perpetuating” character of chronic synovial 
inflammation. Dashed lines indicate possible alternate routes that lead to tissue 
destruction, e.g.: A, via immune cytolysis; B, via lysosomal enzymes; C, via anoxia; 
D & E, via enzymatic attack. (From Castor.“ By permission of Arthritis & Rheuma- 
tism.) 
Castor: Connective Tissue Activation 315 
of CTAP. Second, neither cortisol nor cycloheximide inhibit the “CTAP- 
mimicking” effects of either PGE, or  dibutyryl cyclic AMP. 
In FIGURE, 6 the locus of CTAP-induced connective tissue activation is 
shown at  the junction of the exudative and reparative phases of simple inflamma- 
tion. It is possible that other “signals” may initiate cell proliferation, collagen 
synthesis, and so on. If simple inflammation is amplified by addition of immune 
reactions, the overall picture might be represented as illustrated in FIGURE 7. 
In the context of this scheme, the performance of a drug in chronic inflamma- 
tion would depend on how effectively it inhibited a particular pathway and on  
the relative importance of the different pathways with respect to  tissue destruc- 
tion and perpetuation of the inflammatory process. Presently, we have n o  
quantitative methods for  weighing the importance of the different components 
of the inflammatory process outlined in FIGURE 7, either in terms of their 
proportional contributions to tissue dysfunction and destruction o r  in terms of 
their contribution to the self-perpetuating character of chronic inflammation. 
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DISCUSSION 
DR. M. ZIFF: If you start a rheumatoid synovial cell culture, does it act 
like a rheumatoid synovial cell culture through many, many generations, as 
though it’s producing CTAP all the time? 
DR. CASTOR: That’s correct. 
DR. ZIFF: Now, if you add C T A P  to a normal synovial cell culture and 
stimulate it, does it stay that way forever? 
DR. CASTOR: No, if we add CTAP on a one-time basis, we can demonstrate 
the hypermetabolic effects for  as long as a month. If, however, we add CTAP 
daily or three times a week to normal cultures and not only follow the metabolic 
parameters but also extract the synovial cells for  CTAP, we can recover the 
added CTAP for a few days after it has been omitted from the medium. 
DR. ZIFF: It runs down. 
DR. CASTOR: It runs down very rapidly. This experience with normal 
cultures suggests that the increased amount of CTAP found in rheumatoid 
fibroblasts is unlikely to  be a legacy from their previous contact with leukocytes 
in the joint. 
DR. ZIFF: Have you ever injected it intraarticularly? 
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DR. CASTOR: When you inject both heat-inactivated and nonheat-inactivated 
CTAP into dog joints, there is substantial stimulation of hyaluronate synthesis 
and lactate formation on the experimental side, and the synovial membrane 
exhibits marked reduplication of the lining cell layer. 
DR. ZIFF: Do you think this factor could be responsible for the hypertrophy 
and proliferation of the lining there? 
DR. CASTOR: I can’t be certain. The reason that this experiment wasn’t 
presented is that we also stimulated a substantial influx of polymorphonuclear 
leukocytes into the joint, and the effect of the CTAP and other actions of the 
leukocytes couldn’t be separated. 
DR. S. WIENER (Long Island Jewish Hillside Medical Center, New Hyde 
Park, N . Y . )  : Is it true that CTAP has no effect on dermal fibroblasts, only on 
synovial fibroblasts? 
DR. CASTOR: That’s one of the puzzling aspects of this study, Dr. Wiener. 
What we would call conventional CTAP, that which is derived from either 
lymphocytes or the spleen, has virtually no effect on dermal fibroblasts. 
However, if we use the same extraction and purification procedures and 
extract dermal fibroblasts themselves, we get a CTAP-like material that will 
stimulate both dermal and synovial fibroblasts. So, there may be more than 
one kind of CTAP. 
DR. CRAIG (Boston, M a s s . ) :  CTAP is probably very specific in terms of 
what it affects. It affects fibroblasts from specific sources and only synovial 
cells. Is that right? 
DR. CASTOR: This material has been studied in a few other cell systems. 
Human retroorbital fibroblasts in culture are stimulated by CTAP, as are human 
mesothelioma tumor cells. We presently are isolating fibroblast strains from 
other anatomic locations to work out this question. 
DR. CRAIG: But, when you take CTAP from a human source and add it 
to animal fibroblasts, there is no effect, is that correct? 
DR. CASTOR: Dog synovial membrane cells are stimulated by both human 
and canine CTAP, and that is the only nonhuman synovial cell source that 
we’ve examined. 
